Kadmon Holdings Inc (KDMN) - Financial and Strategic SWOT Analysis Review

  • ID: 4392780
  • SWOT Analysis
  • 47 pages
  • GlobalData
  • Kadmon Corporation
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • MORE
Kaman Holdings Inc (KDMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Kaman Holdings Inc (Kaman) is an integrated biopharmaceutical company that discovers, develops and markets small molecules and biologics for autoimmune and fibroid diseases, various types of cancer, and genetic diseases. The company’s pipeline encompasses investigational candidates for the treatment of moderate to severe psoriasis, non-small cell lung cancer, idiopathic pulmonary fibrosis, glioblastoma, and poly cystic kidney disease. Its pipeline candidates are based on its small molecule and biologics platforms. It also develops in-licensed product candidates and technologies. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline candidates. Kaman is headquartered in New York, the US.

Kaman Holdings Inc Key Recent Developments

Aug 09, 2018: Kaman provides business update and reports second quarter 2018 financial results
May 08, 2018: Kaman Provides Business Update and Reports First Quarter 2018 Financial Results
Mar 06, 2018: Kaman Reports Fourth Quarter And Full Year 2017 Financial Results
Nov 09, 2017: Kaman Provides Business Update and Reports Third Quarter 2017 Financial Results
Aug 11, 2017: Kaman to Present Preclinical Data on ROCK Inhibition in Pulmonary Fibrosis at IPF Summit 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • MORE
Section 1 - About the Company
Kadmon Holdings Inc - Key Facts
Kadmon Holdings Inc - Key Employees
Kadmon Holdings Inc - Key Employee Biographies
Kadmon Holdings Inc - Major Products and Services
Kadmon Holdings Inc - History
Kadmon Holdings Inc - Company Statement
Kadmon Holdings Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis
Company Overview
Kadmon Holdings Inc - Business Description
R&D Overview
Kadmon Holdings Inc - Corporate Strategy
Kadmon Holdings Inc - SWOT Analysis
SWOT Analysis - Overview
Kadmon Holdings Inc - Strengths
Kadmon Holdings Inc - Weaknesses
Kadmon Holdings Inc - Opportunities
Kadmon Holdings Inc - Threats
Kadmon Holdings Inc - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
Kadmon Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Kadmon Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Kadmon Holdings Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments
Aug 09, 2018: Kadmon provides business update and reports second quarter 2018 financial results
May 08, 2018: Kadmon Provides Business Update and Reports First Quarter 2018 Financial Results
Nov 09, 2017: Kadmon Provides Business Update and Reports Third Quarter 2017 Financial Results
Aug 11, 2017: Kadmon to Present Preclinical Data on ROCK Inhibition in Pulmonary Fibrosis at IPF Summit 2017
Aug 03, 2017: Kadmon Provides Business Update and Reports Second Quarter 2017 Financial Results
Jun 01, 2017: Kadmon Announces Data Demonstrating the Potential of the Company’s New GLUT Inhibitors for the Treatment of Autoimmune and Inflammatory Conditions
May 15, 2017: Kadmon Provides Business Update and Reports First Quarter 2017 Financial Results
Mar 22, 2017: Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results

Section 6 – Appendix
Methodology
Ratio Definitions
About
Contact Us
Disclaimer

List of Tables
Kadmon Holdings Inc, Key Facts
Kadmon Holdings Inc, Key Employees
Kadmon Holdings Inc, Key Employee Biographies
Kadmon Holdings Inc, Major Products and Services
Kadmon Holdings Inc, History
Kadmon Holdings Inc, Subsidiaries
Kadmon Holdings Inc, Key Competitors
Kadmon Holdings Inc, Ratios based on current share price
Kadmon Holdings Inc, Annual Ratios
Kadmon Holdings Inc, Interim Ratios
Kadmon Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Kadmon Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Kadmon Holdings Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Kadmon Holdings Inc, Performance Chart (2013 - 2017)
Kadmon Holdings Inc, Ratio Charts
Kadmon Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Kadmon Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Merck & Co Inc
  • Janssen Pharmaceuticals Inc
  • Gilead Sciences Inc
  • AbbVie Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll